Clinical trial · no report yet · Phase 1
NCT03486067
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma
- NCT03486067 ↗
- Terminated
- Celgene
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma
- Phase
- Phase 1
- Status
- Terminated
- Conditions
- Multiple Myeloma
- Interventions
- CC-93269
- Arms
- Administration of CC-93269 · Experimental
- Enrollment
- 183
- Primary outcomes
- Adverse Events (AEs)
- Dose Limiting Toxicity (DLT)
- Non-Tolerated Dose (NTD)
- Maximum Tolerated Dose (MTD)
- Sponsor
- Celgene
- Start
- Apr 3, 2018
- Primary completion
- Mar 18, 2025
- Results posted
- No
- Registry record
- NCT03486067 · updated Apr 17, 2025